SEATTLE, April 8 /PRNewswire-FirstCall/ -- Dendreon Corporation today announced that Varun Nanda has joined the company as senior vice president of global commercial operations, effective April 19, 2010. Mr. Nanda most recently served as the senior vice president and global head of oncology at Roche/Genentech, where he led the global product strategy for all oncology molecules, from pre-clinical research through commercialization.
"With more than twenty years of commercial experience, Varun will help guide our team as we move closer to realizing our mission of transforming the lives of cancer patients," said Hans Bishop, executive vice president and chief operating officer. "Varun's depth of experience launching Avastin(R) and leading several breakthrough global oncology products will be highly relevant to our transformation from a purely R&D organization into a world-class commercial organization."
Mr. Nanda received an M.B.A. from Eastern Illinois University, and a B.E. from Delhi College of Engineering.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.
Dendreon Corporation
